Patients with gastrointestinal tumors may have increased risk of developing other cancers
the ONA take:
According to a recent study published in the journal Cancer, researchers at the University of California San Diego School of Medicine have found that patients with gastrointestinal stromal tumors (GIST) have a higher risk of developing additional malignancies before and after their diagnosis of GIST.
Specifically, the study showed that one in 5.8 patients with GIST will develop other sarcomas, carcinoid tumors, non-Hodgkin's lymphoma, melanoma, breast, colorectal, esophageal, hepatobiliary, non-small cell lung, pancreatic, prostate, and renal cell cancers.
Results also showed that when compared to the general U.S. population, patients with GIST had a 44% increased prevalence of cancers occurring before a diagnosis of GIST and a 66% increased risk of developed other cancers following diagnosis.
"Patients diagnosed with gastrointestinal stromal tumors may warrant consideration for additional screenings based on the other cancers that they are most susceptible to contract," said co-author James D. Murphy, MD, assistant professor of radiation oncology and UC San Diego Moores Cancer Center radiation oncologist.
Patients with gastrointestinal stromal tumors have a higher risk of developing additional malignancies before and after diagnosis.
Sign Up for Free e-newsletters
- Education May Better Equip Nurses to Hold End-of-Life Conversations in Advanced Cancer
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|